The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

CHEMBL117487     (E)-2-propylpent-2-enoic acid

Synonyms: AG-G-72424, trans-2-en-Vpa, delta2,3 Vpe, LS-102099, LS-176074, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of trans-2-Ene-valproic acid


High impact information on trans-2-Ene-valproic acid


Biological context of trans-2-Ene-valproic acid


Anatomical context of trans-2-Ene-valproic acid

  • In this mouse model, valproic acid induced between 20% (400 mg/kg dose) and 60% (600 mg/kg dose) incidence of exencephaly in living fetuses; 2-en-valproic acid was not teratogenic at these dose levels [9].


  1. Acute valproic acid overdose. Clinical course and pharmacokinetic disposition of valproic acid and metabolites. Dupuis, R.E., Lichtman, S.N., Pollack, G.M. Drug safety : an international journal of medical toxicology and drug experience. (1990) [Pubmed]
  2. Valproic acid and active unsaturated metabolite (2-en): transfer to mouse liver following human therapeutic doses. Nau, H., Loscher, W. Biopharmaceutics & drug disposition. (1985) [Pubmed]
  3. Valproic acid: brain and plasma levels of the drug and its metabolites, anticonvulsant effects and gamma-aminobutyric acid (GABA) metabolism in the mouse. Nau, H., Löscher, W. J. Pharmacol. Exp. Ther. (1982) [Pubmed]
  4. Correlation of in vitro anti-proliferative potential with in vivo teratogenicity in a series of valproate analogues. Courage-Maguire, C., Bacon, C.L., Nau, H., Regan, C.M. Int. J. Dev. Neurosci. (1997) [Pubmed]
  5. Diffusion analysis of valproate and trans-2-en-valproate in agar and in cerebral cortex of the rat. Lücke, A., Lehmenkühler, A., Altrup, U., Nicholson, C., Reith, H., Schmitz-Moormann, C., Speckmann, E.J. Brain Res. (1993) [Pubmed]
  6. Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver. II. Influence of phenobarbital comedication. Löscher, W., Nau, H., Wahnschaffe, U., Hönack, D., Rundfeldt, C., Wittfoht, W., Bojic, U. Epilepsy Res. (1993) [Pubmed]
  7. Pharmacokinetics, anticonvulsant efficacy, and adverse effects of trans-2-en-valproate after acute and chronic administration in amygdala-kindled rats. Hönack, D., Rundfeldt, C., Löscher, W. Naunyn Schmiedebergs Arch. Pharmacol. (1992) [Pubmed]
  8. Pharmacokinetics and enterohepatic circulation of (E)-2-ene valproic acid in the rat. Singh, K., Orr, J.M., Abbott, F.S. J. Pharmacobio-dyn. (1990) [Pubmed]
  9. Zinc concentrations in mouse embryo and maternal plasma. Effect of valproic acid and nonteratogenic metabolite. Wegner, C., Drews, E., Nau, H. Biological trace element research. (1990) [Pubmed]
WikiGenes - Universities